Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy

$1.46bn Deal Biggest Ever In Korean Biopharma

botulinum toxin
GS-CBC Consortium Becomes Largest Shareholder Of Hugel • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia